Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sandoz
The purpose of this study is
1. to monitor short children born SGA who were treated with growth hormone in study EP00-401 for the development of diabetes for a further 10 years after termination of growth hormone treatment
and
2. to report the incidence of anti-rhGH antibodies and of E. coli host cell peptide (HCP) antibodies (ABs) for 6 months after termination of GH treatment.
Age
4–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
All patients who fulfilled the diagnosis SGA, participated in study EP00-401, and received at least one dose of study medication
Written informed consent of patient (for children who can read and/ or understand) and/or parent or legal guardian
You may not be if
Patients unwilling and/or parents/guardians who are not capable of ensuring compliance with the provisions of the study protocol